Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
Faı̈ez Zannad(Inserm), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Martina Brueckmann, Javed Butler(University of Mississippi Medical Center), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(University of London), Christoph Wanner(University of Würzburg), Egon Pfarr(Boehringer Ingelheim (Germany)), Janet Schnee(Boehringer Ingelheim (United States)), Sibylle J. Hauske(Heidelberg University), Stefan D. Anker(German Centre for Cardiovascular Research), João Pedro Ferreira(Inserm), Cordula Zeller(Inserm)
Cited by 276
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k